Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/44529
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWestley, I.-
dc.contributor.authorTaylor, P.-
dc.contributor.authorSalm, P.-
dc.contributor.authorMorris, R.-
dc.date.issued2007-
dc.identifier.citationTherapeutic Drug Monitoring, 2007; 29(5):584-591-
dc.identifier.issn0163-4356-
dc.identifier.issn1536-3694-
dc.identifier.urihttp://hdl.handle.net/2440/44529-
dc.descriptionCopyright © 2007, Lippincott Williams & Wilkins. All rights reserved.-
dc.description.abstractThe immunosuppressant drug tacrolimus has a narrow therapeutic index and is subject to a large variation in individual bioavailability and clearance. With its narrow therapeutic index, therapeutic drug monitoring is standard clinical practice in the management of transplant recipients. In this study, we report the evaluation of the cloned enzyme donor immunoassay (CEDIA) for the determination of whole-blood tacrolimus concentrations compared with high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) and microparticle enzyme immunoassay (MEIA) using samples obtained from liver (n = 100) and renal (n = 88) transplant recipients. Linear regression analysis showed a relationship of CEDIA = 1.24 HPLC-MS/MS -0.18 (r = 0.81). The mean bias (+/-SEM) for all patients when compared with HPLC-MS/MS was 22.2% (+/-2.1%). The precision of the CEDIA method for all samples showed a root mean square error of 3.1 microg/L. Liver transplant recipient samples showed a mean (+/-SEM) bias compared with HPLC-MS/MS of 12.5% (+/-1.6%). The precision of the CEDIA method for these samples showed a root mean square error of 1.5 microg/L. The data suggest that in the renal transplant group, the CEDIA and MEIA methods have a bias of 33.3% and 20.1%, respectively, compared with HPLC-MS/MS. The CEDIA tacrolimus immunoassay has been shown to be a rapid method for the determination of whole-blood tacrolimus concentrations and may be considered when HPLC-MS/MS is not available. When used in the clinical setting with other parameters, it would be a useful adjunct in the management of liver transplant recipients, but a significant bias in renal transplant patients needs to be further investigated.-
dc.language.isoen-
dc.publisherLippincott Williams & Wilkins-
dc.subjectClone Cells-
dc.subjectHumans-
dc.subjectTacrolimus-
dc.subjectImmunosuppressive Agents-
dc.subjectDrug Monitoring-
dc.subjectImmunoenzyme Techniques-
dc.subjectKidney Transplantation-
dc.subjectLiver Transplantation-
dc.subjectChromatography, High Pressure Liquid-
dc.subjectReproducibility of Results-
dc.subjectAdolescent-
dc.subjectAdult-
dc.subjectAged-
dc.subjectMiddle Aged-
dc.subjectChild-
dc.subjectFemale-
dc.subjectMale-
dc.subjectMass Spectrometry-
dc.titleCloned enzyme donor immunoassay tacrolimus assay compared with high-performance liquid chromatography-tandem mass spectrometry and microparticle enzyme immunoassay in liver and renal transplant recipients-
dc.typeJournal article-
dc.identifier.doi10.1097/FTD.0b013e31811f25df-
pubs.publication-statusPublished-
Appears in Collections:Aurora harvest 6
Pharmacology publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.